United States · Bill · S
S. 4302 (117th)
Biologics Market Transparency Act of 2022
Introduced
25 May 2022
Last action
—
Status
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709)
Sponsors
—
Subjects
Discovery layer
Source updated
21 April 2025
Summary
Biologics Market Transparency Act of 2022 This bill requires biologics manufacturers to notify the Food and Drug Administration in advance of withdrawing a product from sale.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in Senate (text)
Introduced in Senate · EN · 25 May 2022
Introduced in Senate (PDF)
Introduced in Senate · EN · 25 May 2022
Introduced in Senate
summary · EN · 25 May 2022
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/117th-congress/senate-bill/4302
- Open data entity: https://api.congress.gov/v3/bill/117/s/4302